• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,861.65 302.41
( 0.41%)
Global Indices
Nasdaq
49,785.17 59.69
(0.12%)
Dow Jones
7,421.51 -12.33
(-0.17%)
Hang Seng
63,198.64 456.07
(0.73%)
Nikkei 225
10,253.59 -15.84
(-0.15%)
Forex
USD-INR
95.14 0.72
(0.77%)
EUR-INR
111.99 0.76
(0.69%)
GBP-INR
129.47 0.85
(0.66%)
JPY-INR
0.61 0.00
(0.51%)

EQUITY - MARKET SCREENER

Durlax Top Surface Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
92396
INE0OUW01013
36.949211
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DURLAX
19.31
144.66
EPS(TTM)
Face Value()
Div & Yield %
2.59
10
0
 

dr reddys laboratories ltd
Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03
Jan 01,2026
AVT03 is a proposed biosimilar to Amgen’s Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company’s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.